Who are Intravenous Ketamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane Inhalational Induction and Maintenance, Methoxyflurane, MEOF, Sevoflurane+Nitrous oxide, Desflurane Inhalant Product, Magnesium sulfate 33% solution, MgSO4 plus Ropivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-ketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Intravenous Ketamine — Competitive Intelligence Brief

Intravenous Ketamine (Intravenous Ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dissociative anesthetic. Area: Neuroscience.

marketed Dissociative anesthetic NMDA receptors Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Ketamine (Intravenous Ketamine) — Rebecca Price.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous Ketamine TARGET	Intravenous Ketamine	Rebecca Price	marketed	Dissociative anesthetic	NMDA receptors
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels
Methoxyflurane, MEOF	Methoxyflurane, MEOF	Sunnybrook Health Sciences Centre	marketed	Volatile halogenated ether anesthetic	GABA receptors, NMDA receptors
Sevoflurane+Nitrous oxide	Sevoflurane+Nitrous oxide	Huazhong University of Science and Technology	marketed	General anesthetic (volatile anesthetic + inhalational anesthetic)	GABA receptors, NMDA receptors
Desflurane Inhalant Product	Desflurane Inhalant Product	Sichuan Provincial People's Hospital	marketed	Volatile inhalational anesthetic	GABA receptors, NMDA receptors, potassium channels
Magnesium sulfate 33% solution	Magnesium sulfate 33% solution	The Baruch Padeh Medical Center, Poriya	marketed	Electrolyte supplement / anticonvulsant	Voltage-gated calcium channels, NMDA receptors
MgSO4 plus Ropivacaine	MgSO4 plus Ropivacaine	Hospital Universiti Sains Malaysia	marketed	Local anesthetic adjuvant combination	Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dissociative anesthetic class)

Rebecca Price · 1 drug in this class
The University of Hong Kong · 1 drug in this class
Unity Health Toronto · 1 drug in this class
University Tunis El Manar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-ketamine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab